Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 287 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aromatase Inhibitors Clear all
Recruiting Phase 2 Interventional

Enhanced Pain Coping in Cancer (EPIC): A Study of Managing Treatment-Related Joint Pain in Breast Cancer Survivors

NCT06728579
View directory record Official record
Conditions
Breast Cancer Survivor
Interventions
Mindfulness Oriented Recovery Enhancement (MORE), Questionnaires, Supportive Psychotherapy (SG)
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
San Diego, California • Tallahassee, Florida • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 15, 2026, 10:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors

NCT01074320
View directory record Official record
Conditions
Breast Cancer
Interventions
Other
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Robbinsdale, Minnesota • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Sep 15, 2026, 10:53 AM EDT
Completed No phase listed Observational

The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins

NCT01341171
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 15, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

NCT00240071
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Avastin, Hormonal therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 15, 2026, 10:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798
View directory record Official record
Conditions
Locally Advanced or Metastatic Breast Cancer
Interventions
Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 15, 2026, 10:53 AM EDT
Completed Not applicable Interventional

The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.

NCT02057536
View directory record Official record
Conditions
Women With ER Positive Breast Cancer Taking (AI) w Joint Discomfort and Stiffness
Interventions
Arm A Directed exercise program, Observation
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
40 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 15, 2026, 10:53 AM EDT
Completed No phase listed Observational

Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms

NCT02118636
View directory record Official record
Conditions
Breast Cancer, Arthralgia
Interventions
Not listed
Lead sponsor
Lynn Henry
Other
Eligibility
21 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced Sep 15, 2026, 10:53 AM EDT
Suspended Phase 2 Interventional

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

NCT06538389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Breast Adenocarcinoma, Breast Ductal Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma, Progesterone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, BRC-001, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 15, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

NCT01216176
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, AZD0530 (saracatinib), Placebo
Drug
Lead sponsor
Joyce Marie Slingerland, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 15, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional

Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors

NCT00930527
View directory record Official record
Conditions
Breast Cancer
Interventions
Omega-3 Fatty Acid
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Sep 15, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

NCT01004081
View directory record Official record
Conditions
Breast Cancer
Interventions
BIIB021, exemestane (Aromasin)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
19
States / cities
Alabaster, Alabama • Encinitas, California • Gilroy, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 15, 2026, 10:53 AM EDT
Active, not recruiting Phase 1 Interventional

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

NCT04895761
View directory record Official record
Conditions
Breast Cancer
Interventions
DPX-Survivac, Letrozole 2.5mg, Cyclophosphamide 50mg, XRT 10Gy x2
Biological · Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 15, 2026, 10:53 AM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 15, 2026, 10:53 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Gilbert, Arizona • Burbank, California • Corona, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 15, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Results available

Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)

NCT02959853
View directory record Official record
Conditions
Hypogonadism, Severe Obesity
Interventions
Anastrazole, weight loss
Drug · Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
35 Years to 65 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 15, 2026, 10:53 AM EDT
Completed No phase listed Observational

Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

NCT03505736
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Premenopausal, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Adenosine, Magnetic Resonance Imaging, Regadenoson, Stress Management Therapy
Biological · Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 55 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 15, 2026, 10:53 AM EDT
Enrolling by invitation Phase 3 Interventional

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

NCT05645536
View directory record Official record
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 51 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
17
States / cities
Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 15, 2026, 10:53 AM EDT
Recruiting Phase 1 Interventional

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

NCT06139107
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Letrozole
Drug
Lead sponsor
Mridula George, MD
Other
Eligibility
60 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
4
States / cities
Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 15, 2026, 10:53 AM EDT
Completed Early Phase 1 Interventional Results available

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

NCT01697345
View directory record Official record
Conditions
Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
Interventions
Testosterone
Drug
Lead sponsor
Creighton University
Other
Eligibility
50 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 15, 2026, 10:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

NCT06557057
View directory record Official record
Conditions
HER2-Positive Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 15, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Biology Guided Therapy for Breast Cancer for ER Positive

NCT04965688
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Biopsy-Guided Therapy Selection
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 15, 2026, 10:53 AM EDT
Suspended Not applicable Interventional

Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00433173
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years to 75 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 15, 2026, 10:53 AM EDT
Active, not recruiting Phase 1 Interventional

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

NCT03959891
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Fulvestrant, Aromatase Inhibitor, Palbociclib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 15, 2026, 10:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors

NCT01272570
View directory record Official record
Conditions
Breast Cancer, Xerostomia
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 15, 2026, 10:53 AM EDT